• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Galecto Inc.

    11/13/25 5:26:42 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLTO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Galecto, Inc.

    (Name of Issuer)


    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)


    36322Q206

    (CUSIP Number)


    11/12/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    36322Q206


    1Names of Reporting Persons

    Point72 Asset Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    100,001.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    100,001.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    100,001.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    36322Q206


    1Names of Reporting Persons

    Point72 Capital Advisors, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    100,001.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    100,001.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    100,001.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    36322Q206


    1Names of Reporting Persons

    Steven A. Cohen
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    100,001.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    100,001.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    100,001.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Galecto, Inc.
    (b)Address of issuer's principal executive offices:

    75 State Street, Suite 100, Boston, MA 02109
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.00001 per share ("Shares"), of Galecto, Inc. (the "Issuer") held by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the Shares held by Point72 Associates; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act").
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
    (c)Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.00001 per share
    (e)CUSIP No.:

    36322Q206
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on November 12, 2025. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein. The aggregate percentage of the Shares reported to be beneficially owned by each Reporting Person is based on 1,592,521 Shares outstanding, which is the sum of: (i) 1,327,212 Shares outstanding as of November 7, 2025, as reported in Exhibit 2.1 (the "Agreement and Plan of Merger") to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on November 10, 2025; and (ii) 265,309 Shares issued in connection with the closing of the Agreement and Plan of Merger, as disclosed therein.
    (b)Percent of class:

    6.3%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on November 12, 2025.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on November 12, 2025.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on November 12, 2025.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on November 12, 2025.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Shares.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Point72 Asset Management, L.P.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:11/13/2025
     
    Point72 Capital Advisors, Inc.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:11/13/2025
     
    Steven A. Cohen
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:11/13/2025
    Exhibit Information

    Exhibit 99.1: Joint Filing Agreement

    Get the next $GLTO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLTO

    DatePrice TargetRatingAnalyst
    8/6/2021$12.00 → $7.00Outperform
    Credit Suisse
    More analyst ratings

    $GLTO
    SEC Filings

    View All

    SEC Form D filed by Galecto Inc.

    D - Galecto, Inc. (0001800315) (Filer)

    11/21/25 4:02:14 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Galecto Inc.

    SCHEDULE 13G - Galecto, Inc. (0001800315) (Subject)

    11/13/25 5:26:42 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure

    8-K - Galecto, Inc. (0001800315) (Filer)

    11/10/25 8:19:04 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Fairmount Funds Management Llc

    3 - Galecto, Inc. (0001800315) (Issuer)

    11/17/25 9:48:40 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Cain Christopher W.

    3 - Galecto, Inc. (0001800315) (Issuer)

    11/17/25 9:45:06 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Bruno Julianne claimed ownership of 8,032 shares (SEC Form 3)

    3 - Galecto, Inc. (0001800315) (Issuer)

    11/17/25 9:44:24 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $GLTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Galecto Announces Acquisition of Damora Therapeutics

    Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative Neoplasms  Damora Therapeutics, the sixth company launched based on assets developed by Paragon Therapeutics, is advancing a portfolio of anti-mutant calreticulin (mutCALR) targeted therapies, led by DMR-001, a potentially best-in-class monoclonal antibody targeting mutCALR Combined company with complementary assets expected to have financial runway into 2029 to support multiple data milestones, including Phase 1 clinical proof-of-concept data for DMR-001 anticipated in 2027 BOSTON,

    11/10/25 7:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Reports Third Quarter 2025 Operating and Financial Results

    BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced its operating and financial results for the quarter ended September 30, 2025. "During the quarter, we received constructive regulatory guidance from the FDA on our pre-IND submission for GB3226, a novel small molecule dual inhibitor of ENL-YEATS and FLT3 with potential to address a broad portion of patients with acute myeloid leukemia (AML), including those with high-risk genetic mutations," said Dr. Hans Schambye, CEO of Galecto. "We are encouraged by this regulatory feedback, which al

    11/6/25 4:30:00 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Reports Second Quarter 2025 Operating and Financial Results

    BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended June 30, 2025. "We remain focused on advancing our lead program, GB3226, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML," said Dr. Hans Schambye, CEO of Galecto. "Our goal is to submit an Investigational New Drug (IND) application to the FDA in Q1 2026, and we are actively advancing key IND-enabling activities across pharmacology, toxicology, and CMC to support a smooth transition into the clinic." Preclinical

    8/5/25 4:15:00 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Credit Suisse reiterated coverage on Galecto with a new price target

    Credit Suisse reiterated coverage of Galecto with a rating of Outperform and set a new price target of $7.00 from $12.00 previously

    8/6/21 10:59:40 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Credit Suisse resumed coverage on Galecto with a new price target

    Credit Suisse resumed coverage of Galecto with a rating of Outperform and set a new price target of $12.00

    4/26/21 8:53:50 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Credit Suisse Group reiterated coverage on Galecto with a new price target

    Credit Suisse Group reiterated coverage of Galecto with a rating of Outperform and set a new price target of $12.00 from $29.00 previously

    3/16/21 8:17:33 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Financials

    Live finance-specific insights

    View All

    Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

    Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML)BRM-1420 has the potential for enhanced clinical effectiveness compared to FLT3 inhibitors alone and has shown synergistic effects with SOC in preclinical models BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to f

    10/7/24 8:45:46 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

    Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseasesFindings to be discussed in a conference call and virtual webinar today, November 8, 2022, at 8 a.m. ET BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced it will discuss topline data and additional analyses from its recently completed Phase 1b/2a GULLIVER-2 trial (NCT05009680), including the observed statistically significant signs of liver protection, in a conference call and virt

    11/8/22 6:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

    Late-breaking oral and poster presentations include clinical and preclinical data related to GULLIVER-2 clinical trialGalecto to host a webinar at 8:00 a.m. ET on Tuesday, November 8, 2022 to discuss expanded topline data and analysis BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present data from its recently completed Phase 1b/2a GULLIVER-2 trial at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2022 being held in Washington, D.C. on November 4-8, 2022. G

    10/31/22 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Leadership Updates

    Live Leadership Updates

    View All

    Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

    BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique combination of expertise and a proven track record of leadership in the healthcare industry. "We are thrilled to welcome Dr. Wechsler to our Board of Directors," said Dr. Carl Goldfischer, Chair of the Board of Galecto. "Amy is a distinguished physician who has board certification in both dermatology and psychiatry. Her experience guiding companies through critical growth stages make her an important add

    10/15/24 8:30:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer

    BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of a highly experienced biotech and pharmaceuticals executive Stephanie Oestreich, PhD, MPA as Chief Business Officer, a newly-created position at Galecto. Dr. Oestreich joins Galecto from Mnemo Therapeutics where she served as Vice President of Operations and Head of Alliance Management. She previously held the role of Executive Vice President at Evotec, a biotech company focusing on developing and delivering new medicines, and has previously served in a number of senior roles

    1/5/22 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Appoints Garrett Winslow as General Counsel

    BOSTON, May 11, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Garrett Winslow has joined the Company as Senior Vice President, General Counsel. In this role, Mr. Winslow will lead the Company's legal, compliance and enterprise risk management functions, reporting to Hans Schambye, CEO. Garrett Winslow brings to Galecto over 15 years of experience working with public companies in the life sciences industry. Prior to joining Galecto, he served as the General Counsel of Spring Bank Pharmaceuticals.  He was also a partner in the Corporate and Securitie

    5/11/21 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Galecto Inc.

    SC 13G/A - Galecto, Inc. (0001800315) (Subject)

    11/7/24 3:07:49 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Galecto Inc.

    SC 13G - Galecto, Inc. (0001800315) (Subject)

    11/7/24 2:55:56 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Galecto Inc.

    SC 13G/A - Galecto, Inc. (0001800315) (Subject)

    8/29/24 5:59:56 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care